Rezdiffra net sales surged 71% year-over-year to $364.3M in 2Q26, with patient growth more than doubling. The MASH market is expanding rapidly, and pipeline advancements and new patents position the company for further growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.